Pawel Bialk is the associate director of technology development for the Gene Editing Institute. His current areas of focus are novel target discovery and overseeing in-vitro validation of novel targets for therapeutic pipeline development. Additionally, Pawel is the subject matter expert on CRISPR off-target safety profiling for pre-IND development. He received his B.S. from Mercyhurst University and his M.S. in biology from Delaware State University, where he studied the potential of designer nucleases, such as TALENs and CRISPR systems, in conjunction with single-stranded DNA repair templates to enhance the efficiency of specific events in the gene editing reaction.
